Skip to content

Gyre Therapeutics

Primary Menu

About
Science
Investors
Contact

Mitigation of Injection Site Reactions after Subcutaneous Administration of Dalcinonacog Alfa (DalcA) in Hemophilia B Using Preclinical Models

Post navigation

Previous: Dose Selection For Subcutaneous Marzeptacog Alfa (Activated) In Subjects With Factor VII Deficiency Using Population Pharmacometric Clinical Trial Simulations

Next: Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

About
- Management Team
- Board of Directors
Science
Investors
Contact

Gyre Therapeutics

Gyre Therapeutics, Inc.
| 12770 High Bluff Drive, Suite 150,
San Diego, CA 92130

© Gyre Therapeutics, Inc. All rights reserved.
Terms of Use Privacy Policy

X

Previous

Next